# Enhancing Relapse Prevention with rTMS: Dose-Response Parameters for Smoking Cessation

> **NIH NIH R01** · ROSWELL PARK CANCER INSTITUTE CORP · 2021 · $568,590

## Abstract

Project Summary / Abstract. Tobacco use remains a significant cause of death and disease. Most smokers
want to quit. Over half make a quit attempt every year, but over 90% relapse within 12 months, choosing the
immediate reinforcement of smoking over the long-term benefits of quitting. Innovative methods for preventing
relapse are needed. The Competing Neurobehavioral Decision Systems (CNDS) model posits that decisions
are driven by interactions between the executive function network, located in the prefrontal cortex (PFC); and
the impulsive network, located in limbic and paralimbic brain regions. Behavioral economic, neuroimaging,
neurobiological, and neurobehavioral studies support this conceptualization. Greater PFC activity is linked with
more self-control, more prudent choices, decreased delay discounting rates, and increased abstinence rates.
The dorsolateral prefrontal cortex (DLPFC), a functional node in the PFC, has a significant role in executive
function network. We propose that increasing activity in the DLPFC will reduce relapse to smoking.
High frequency repetitive transcranial magnetic stimulation (rTMS) selectively modulates neuronal activity. In a
randomized, double-blind, sham-controlled trial, we found 8 sessions (1/day), active or sham 20Hz rTMS (900
pulses) of the left DLPFC combined with a cognitive-behavioral intervention (CBI) to increase latency to
relapse, short-term abstinence rates, and delay discounting The mean/median latency to relapse for active
rTMS was n=45.2 and n=33.5 days compared with n=20.5 and n=8 days for sham. Active rTMS reduced the
relative risk of relapse 3-fold (RR 0.29, CI 0.10-0.76, p =.01). Active rTMS also increased 12-week abstinence
rates (50% vs. 15.4%, p=.05), decreased delay discounting rates, and increased the uptake of the CBI. While
this evidence is compelling, an optimal dosing strategy must be determined before a long-term efficacy trial
can be conducted. The goal of this project is to determine a dosing strategy for 20Hz rTMS that will
produce the best long-term abstinence outcomes with the fewest undesirable effects.
We will use a fully crossed, double-blinded, randomized factorial design with three factors: duration (stimulation
days: 8, 12, and 16), intensity (900 or 1800 pulses per day), and a sham control for each condition. The sham
control will allow for a comparison group to calculate effect sizes and account for non-specific treatment-related
effects. Outcomes will include latency to relapse, 12 and 24-week point prevalence abstinence rates, delay
discounting rates, cognitive-behavioral skills acquisition, and potential undesirable effects (e.g., non-
compliance due to participant burden). Aim One will examine the effects of stimulation duration and intensity
on all outcomes among motivated smokers (n=258). Aim Two will identify the most promising dosing strategy
by systematically balancing effect sizes and undesirable effects. Establishing a dose-response relationship is
criti...

## Key facts

- **NIH application ID:** 10163136
- **Project number:** 5R01CA229415-04
- **Recipient organization:** ROSWELL PARK CANCER INSTITUTE CORP
- **Principal Investigator:** Christine Elizabeth Sheffer
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $568,590
- **Award type:** 5
- **Project period:** 2018-06-01 → 2023-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10163136

## Citation

> US National Institutes of Health, RePORTER application 10163136, Enhancing Relapse Prevention with rTMS: Dose-Response Parameters for Smoking Cessation (5R01CA229415-04). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10163136. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*